Xenocort 0.05% Cream: Each 10 gm cream contains Clobetasol Propionate BP 5 mg.
Xenocort 0.05% Ointment: Each 10 gm ointment contains Clobetasol Propionate BP 5 mg.
1. Initial control of all forms of hyperacute eczema in all age groups 2. Chronic hyperkeratotic eczema of the hands and feet and patches of chronic lichen simplex 3. Chronic hyperkeratotic psoriasis of any area of the body 4. Severe acute photosensitivity 5. Hypertrophic lichen planus 6. Localized bullous disorders 7. Keloid scarring 8. Pretibial myxoedema 9. Vitiligo 10. Suppression of reaction after cryotherapy.
1. Cutaneous infections such as impetigo, tinea corporis and herpes simplex 2. Infestations such as scabies 3. Neonates (Children less than one year old) 4. Acne vulgaris 5. Rosacea 6. Gravitational ulceration.
Dosage & Administration
Apply sparingly to the affected area once or twice daily until improvement occurs. As with other highly active topical steroid preparations, therapy should be discontinued when control is achieved. If a longer course is necessary, it is recommended that treatment should not be continued for more than four weeks without the patient\'s condition being observed. Repeated short courses of Xenocort may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used. In very resistant lesions, especially where there is hyperkeratosis, the anti- inflammatory effect of Xenocort can be enhanced, if necessary, by occluding the treatment area with polythene film. Only overnight occlusion is usually adequate to bring about a satisfactory response. Thereafter, improvement can usually be maintained by application without occlusion.
Provided the weekly dosage is less than 50g in adults, any pituitary-adrenal suppression is likely to be transient with a rapid return to normal values once the short course of steroid therapy has ceased. The same applies to children given proportionate dosage. Use of occlusive dressings increases the absorption of topical corticosteroids. Prolonged and intensive treatment with a highly active corticosteroid preparation may cause atrophic changes, such as thinning, striae and dilatation of the superficial blood vessels, particularly when occlusive dressings are used or where skin folds are involved.
Long term continuous therapy with Clobetasol Propionate should be avoided, particularly in infants and children, in whom adrenal suppression occurs readily. If Clobetasol Propionate is required for use in children, it is recommended that the treatment should be reviewed on weekly basis.
Clobetasol Propionate should be avoided in pregnant women. Mothers using large amounts of the drug should be aware of potential excretion in milk.
No Information provided
Xenocort Cream: Each pack has a tube containing 10 gm of the cream.
Xenocort Ointment: Each pack has a tube containing 10 gm of the ointment.